Vial adds Dr Luke Nordquist to company's Oncology Scientific Advisory Board.

M2 EQUITYBITES-August 4, 2022-Vial adds Dr Luke Nordquist to company's Oncology Scientific Advisory Board

(C)2022 M2 COMMUNICATIONS http://www.m2.com

United States-based contract research organisation Vial announced on Wednesday that it has added Dr Luke Nordquist to the company's Oncology Scientific Advisory Board.

Nordquist, MD, FACP is serving as the CEO of the XCancer Research Network and founded the Urology Cancer Center & GU Research Network. He has become a global Oncology KOL due to his main role in ground-breaking clinical trials from Phase I-IV. He has been serving as the principal investigator on various urologic cancer studies including several first-in-world treatments.

Dr Nordquist said, 'My mission...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT